XBIO Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Xenetic Biosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerXBIO

Market Cap7.5M

Cash RunwayRunway > 12 months

Next CatalystCorporate Update

Public Research Snapshot

Xenetic Biosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Sodium Cridanimod in Endometrial Cancer (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Advancing Innovative Immune-Oncology Technologies	n/a	n/a	n/a	Public pipeline row
Sodium Cridanimod	Endometrial Cancer	n/a	Phase 2	Public pipeline row
PD-1	n/a	n/a	Preclinical	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Corporate Update	Timing not specified	n/a	Low
Presentation	Timing not specified	n/a	Low
Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03077698	Phase 2	TERMINATED	25	2020-07-17

Scientific Context

catalyst_type | Corporate Update
catalyst_type | Presentation
catalyst_type | Corporate Update
catalyst_type | Presentation
catalyst_type | Corporate Update

Want the full XBIO research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.